Abstract:3531 Background: ctDNA has emerged as a promising biomarker for noninvasive monitoring of treatment response and disease progression in many tumor types. However, the clinical use of ctDNA in patients with HCC has not been established. Here, we evaluated longitudinal and personalized detection of ctDNA for monitoring the treatment response to atezolizumab (atezo) + bevacizumab (bev) in patients with unresectable HCC not previously treated with systemic therapy. Methods: A subset (n = 48) of 104 patients with HCC who enrolled in Arm A of GO30140 (NCT02715531; Phase 1b) and received atezo + bev treatment were included in this study. These patients had 10 CR, 11 PR, 12 SD and 15 PD per IRF-assessed RECIST 1.1. Serial plasma samples were collected at baseline (Cycle [C]1 Day [D]1), during treatment (C2D1, C4D1) and at disease progression. Somatic mutations in individual tumors were identified via whole exome sequencing of archival tumor tissues or fresh biopsies collected before treatment. Personalized ctDNA assays (Signatera 16-plex multiplex PCR next-generation sequencing assay) specific to each patient’s tumor mutational signatures were successfully designed for 47 of 48 patients. Results: At C1D1, a median of 25.7 ng of cell-free DNA was extracted from 2-mL plasma samples. ctDNA was detected in 45 of 47 patients (96%), with a median of 70.6 mean tumor molecules/mL of plasma (MTM/mL) and a median of 1.8% mean variant allele frequency (mean VAF) in plasma. Higher ctDNA levels detected at C1D1 appeared to be associated with increased tumor burden ( P < 0.03). Dynamic changes in ctDNA levels post-treatment were associated with response at C4D1. ctDNA status changed from positive at baseline to negative in 7 of 10 CR (70%), 3 of 11 PR (27%), 1 of 11 SD (9%) and 0 of 11 PD (0%) patients. Longer PFS was observed in patients whose ctDNA became undetectable post-treatment. The median PFS in patients with ctDNA present vs cleared at C4D1 was 6.5 months and not reached, respectively (HR, 12 [1.7-93], log-rank P < 0.00029). Conclusions: Our study showed that Signatera, a personalized and tumor-informed ctDNA assay, could be used as a sensitive method for detecting ctDNA in patients with unresectable HCC. More importantly, our results illustrate the promise of ctDNA as an emerging biomarker that may potentially help to monitor treatment responses and disease progression in patients with HCC.

Detecting Circulating Tumor DNA in Hepatocellular Carcinoma Patients Using Droplet Digital PCR Is Feasible and Reflects Intratumoral Heterogeneity

The Diagnostic and Prognostic Usage of Circulating Tumor DNA in Operable Hepatocellular Carcinoma.

Circulating Tumor DNA Correlates with Microvascular Invasion and Predicts Tumor Recurrence of Hepatocellular Carcinoma

Circulating tumor DNA in hepatocellular carcinoma: trends and challenges

Circulating Tumor DNA As an Emerging Liquid Biopsy Biomarker for Early Diagnosis and Therapeutic Monitoring in Hepatocellular Carcinoma

Longitudinal and Personalized Detection of Circulating Tumor DNA (ctdna) for Monitoring Efficacy of Atezolizumab Plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma (HCC).

Application of Plasma Circulating Cell-Free DNA Detection to the Molecular Diagnosis of Hepatocellular Carcinoma.

Molecular profiling of Chinese patients with advanced hepatocellular carcinoma using circulating tumor DNA.

Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments

Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients

Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma

Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma

Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma

Circumventing Intratumoral Heterogeneity to Identify Potential Therapeutic Targets in Hepatocellular Carcinoma.

Noninvasive Detection of Hepatocellular Carcinoma with Circulating Tumor DNA Features and Α-Fetoprotein

Serial Circulating Tumor DNA to Predict Early Recurrence in Patients with Hepatocellular Carcinoma: a Prospective Study.

Discovery and clinical validation of cost-effective noninvasive early detection of hepatocellular carcinoma (HCC) through circulating tumor DNA (ctDNA) methylation signature.

The feasibility of using mutation detection in ctDNA to assess tumor dynamics

Circulating tumor DNA/circulating tumor cells and the applicability in different causes induced hepatocellular carcinoma

The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma

Quantitation of Plasma Circulating DNA Using Quantitative PCR for the Detection of Hepatocellular Carcinoma